We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
Read MoreHide Full Article
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY - Free Report) and United Therapeutics (UTHR - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Merck KGaA is sporting a Zacks Rank of #2 (Buy), while United Therapeutics has a Zacks Rank of #3 (Hold). This means that MKKGY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
MKKGY currently has a forward P/E ratio of 13.58, while UTHR has a forward P/E of 17.06. We also note that MKKGY has a PEG ratio of 3.23. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. UTHR currently has a PEG ratio of 4.96.
Another notable valuation metric for MKKGY is its P/B ratio of 0.53. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, UTHR has a P/B of 3.12.
These are just a few of the metrics contributing to MKKGY's Value grade of A and UTHR's Value grade of C.
MKKGY sticks out from UTHR in both our Zacks Rank and Style Scores models, so value investors will likely feel that MKKGY is the better option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY - Free Report) and United Therapeutics (UTHR - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Merck KGaA is sporting a Zacks Rank of #2 (Buy), while United Therapeutics has a Zacks Rank of #3 (Hold). This means that MKKGY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
MKKGY currently has a forward P/E ratio of 13.58, while UTHR has a forward P/E of 17.06. We also note that MKKGY has a PEG ratio of 3.23. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. UTHR currently has a PEG ratio of 4.96.
Another notable valuation metric for MKKGY is its P/B ratio of 0.53. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, UTHR has a P/B of 3.12.
These are just a few of the metrics contributing to MKKGY's Value grade of A and UTHR's Value grade of C.
MKKGY sticks out from UTHR in both our Zacks Rank and Style Scores models, so value investors will likely feel that MKKGY is the better option right now.